Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 05 Oct 2020
Drinking more than two cups of coffee per day may just be the intervention that prevents hundreds of thousands of liver disease‐related deaths globally, a study reports.
04 Oct 2020
Treatment with antivascular endothelial growth factor (anti-VEGF), along with regular monitoring, minimizes the risk of long-term vision loss in patients with neovascular age-related macular degeneration (AMD), a recent study has shown.
Stephen Padilla, 6 days ago
Use of systemic corticosteroids does not reduce in-hospital mortality for patients with severe or critical coronavirus disease (COVID-19), which is in stark contrast to that observed in the RECOVERY clinical trial, according to a study in Wuhan, China.

Nitrogen-containing bisphosphonates may lower risk of pneumonia in patients with hip fracture

Dr Margaret Shi
18 Aug 2020

N-BP 2
A recent study led by researchers from the University of Hong Kong (HKU) shows that the use of nitrogen-containing bisphosphonates (N-BPs), particularly alendronate, is associated with reduced risks of pneumonia and pneumonia mortality compared with no anti-osteoporotic treatment and non-N-BP anti-osteoporotic treatment.

In the retrospective cohort study, data of 54,047 patients aged ≥50 years with an incident hip fracture who were admitted to hospital via an emergency room between 1 January 2005 and 31 December 2015, and who were diagnosed with or died of pneumonia, were retrieved from the Clinical Data Analysis and Reporting System (CDARS), a population-wide medical database managed by the Hospital Authority (HA). Patients were followed up until 31 December 2016. [J Bone Miner Res 2020, doi: 10.1002/jbmr.4030]

At baseline, 4,041 patients exposed to any N-BPs (ie, alendronate, ibandronate, risedronate and zoledronate) during the study period were matched with 11,802 patients who received no anti-osteoporotic treatment. More than 15 percent (15.8 percent) and 14.3 percent of patients with and without N-BP treatment, respectively, received seasonal influenza vaccine in the past year or pneumococcal vaccine on/before the index date.

Likewise, 1,284 patients with N-BP treatment were matched with 507 patients with non-N-BP anti-osteoporotic treatment, with strontium ranelate, salcatonin, denosumab, teriparatide and raloxifene used in 166, 161, 135, 38 and 7 patients, respectively.

In patients who received N-BPs vs no anti-osteoporotic treatment, the incidence of pneumonia and pneumonia mortality was 6.9 vs 9.0 per 100 person-years and 2.3 vs 3.5 per 100 person-years, respectively, during a median of 2.7 years of follow-up.

Patients treated with N-BPs had a 24 percent lower risk of incident pneumonia (hazard ratio [HR], 0.76; 95 percent confidence interval [Cl], 0.70 to 0.83; p<0.001) vs those with no anti-osteoporotic treatment, translating to an absolute risk difference (ARD) of 0.02 and number needed to treat (NNT) of 46.

A significant risk reduction in pneumonia mortality was also observed in patients who received N-BPs vs no anti-osteoporotic treatment (HR, 0.65; 95 percent CI, 0.56 to 0.75; p<0.001).

“The study included mainly alendronate-exposed patients [81.6 percent],” the researchers noted. Among these patients, similar risk reductions in incident pneumonia (HR, 0.74; 95 percent CI, 0.67 to 0.81; p<0.001) and pneumonia mortality (HR, 0.63; 95 percent CI, 0.54 to 0.74; p<0.001) were observed vs no anti-osteoporotic treatment.

Of note, reductions in risk of incident pneumonia and pneumonia mortality with N-BPs vs no anti-osteoporotic treatment remained significant regardless of gender and vaccination status (incident pneumonia: female, p<0.001; male, p=0.009; vaccination, p=0.007; no vaccination, p<0.001) (pneumonia mortality: female: p<0.001; male, p=0.025; vaccination, p=0.055; no vaccination, p<0.001).

In a secondary analysis, consistent reductions in risk of incident pneumonia and associated mortality were seen with N-BPs vs non-N-BP anti-osteoporotic treatment (incident pneumonia: HR, 0.68; 95 percent CI, 0.53 to 0.87; p=0.002) (pneumonia mortality: HR, 0.60; 95 percent CI, 0.41 to 0.89; p=0.01).

According to the researchers, the study’s results suggest that N-BPs could confer additional protection against pneumonia to compensate for the reported shortage and low acceptance of vaccine, as well as the high cost of large-scale vaccination programmes. “Drug repositioning of N-BPs as a pneumonia prevention drug, especially in high-risk groups [eg, patients with osteoporosis], may be of public health importance,” they suggested.  “Further randomized clinical trials may be warranted to further validate our findings.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Hong Kong digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 05 Oct 2020
Drinking more than two cups of coffee per day may just be the intervention that prevents hundreds of thousands of liver disease‐related deaths globally, a study reports.
04 Oct 2020
Treatment with antivascular endothelial growth factor (anti-VEGF), along with regular monitoring, minimizes the risk of long-term vision loss in patients with neovascular age-related macular degeneration (AMD), a recent study has shown.
Stephen Padilla, 6 days ago
Use of systemic corticosteroids does not reduce in-hospital mortality for patients with severe or critical coronavirus disease (COVID-19), which is in stark contrast to that observed in the RECOVERY clinical trial, according to a study in Wuhan, China.